drugset / Trial / NCT02325180

Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia

NCT02325180

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open label, randomised controlled trial to assess the safety and efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria infection. Molecular markers for antimalarial resistance will also be assessed and the presence of molecular markers in the parasites will be associated with treatment outcomes.

Timeline

Start
2015-01
Primary completion
2015-06
Completion
2015-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 2.25 mg/kg
Comparator Artemether Small molecule 20 mg
Comparator lumefantrine Small molecule 120 mg
Subject piperaquine Small molecule 18 mg/kg